Why the study?
Does low-molecular-weight heparin (LMWH) influence plasma levels of thrombin-antithrombin-III (TAT) and factor VIII activity (VIII:C) in patients undergoing total hip replacement?
Does low-molecular-weight heparin (LMWH) influence plasma levels of thrombin-antithrombin-III (TAT) and factor VIII activity (VIII:C) in patients undergoing total hip replacement?
LMWH prophylaxis does not significantly influence the post-operative increase in TAT and factor VIII activity in patients undergoing total hip replacement, though lower factor VIII activity on day 7 is associated with DVT development.
LMWH does not blunt post-operative TAT or VIII:C rises after hip replacement; challenges presumed mechanism while associating lower day-7 VIII:C with DVT.
In a randomized doubled-blind placebo-controlled study, plasma levels of thrombin-antithrombin-III (TAT) and factor VIII activity (VIII:C) were measured pre-operatively and on days 1, 3, 5 and 7 post-operatively in 70 consecutive patients undergoing total hip replacement. Patients received either a subcutaneous injection of low-molecular-weight heparin (LMWH) or placebo once daily. Post-operative deep vein thrombosis (DVT) was diagnosed by bilateral phlebography. The levels of TAT and VIII:C both increased significantly after operation and were not significantly influenced by LMWH. Thirty-three patients in whom post-operative DVT developed had a significantly lower level of VIII:C on day 7, compared with patients without DVT.
No takes yet. Share an insight, caveat, or question.
oSrensen et al. (1990) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: